Zim Laboratories Ltd. (ZIMLAB) AI Stock Analysis

• Market Cap: ₹3.14B
• Dividend Yield: N/A
• Average Volume (3M): 6.28K
• Price to Earnings (P/E): 20.0
• Beta (1Y): 1.06
• Revenue Growth: -5.82%
• EPS Growth: -59.22%
• Country: IN
• Employees: 556
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.90
• Shares Outstanding: 48,735,813
• 10 Day Avg. Volume: 5,950
• 30 Day Avg. Volume: 6,279
• PEG Ratio: -1.14
• Price to Book (P/B): 1.62
• Price to Sales (P/S): 1.09
• P/FCF Ratio: 1.15K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ₹69.00 ▼(-2.97% Downside)
• Action: Reiterated Date: 10/31/25
• Date: Action: Reiterated 10/31/25

Zim Laboratories Ltd. scores moderately due to strong financial performance with revenue growth and operational efficiency. However, the stock's overvaluation and neutral technical indicators weigh down the overall score. The lack of earnings call and corporate events data limits further insights.

Positive Factors

Diversified revenue streams

ZimLabs sells branded formulations domestically, exports finished dosages, provides contract development/manufacturing and has platform-led opportunities. This multi-channel model reduces single-market risk, supports steadier demand and provides multiple durable growth levers over 2-6 months.

Improving operating cash flow

Sustained improvement in operating cash flow enhances liquidity and working-capital management, enabling the company to fund ongoing operations, support sales growth, and finance necessary capex or regulatory investments without immediate reliance on external financing.

Operational efficiency and margin stability

Improved gross margins and stable EBIT/EBITDA indicate effective cost controls and manufacturing efficiency in oral solid dosages. Consistent operational margins support durable profitability and competitive positioning amid pricing pressure in generics and help absorb incremental investment needs.

Negative Factors

Declining net profit margin

A drop in net margin despite revenue gains suggests rising non-operating costs, higher interest, taxes, or one-off items that reduce retained earnings. Persisting margin compression would limit reinvestment, shareholder returns and could weaken ROE over several quarters.

Low free cash flow

Continued low free cash flow, with capex absorbing most OCF, constrains the firm’s ability to pay down debt, return capital, or invest in new growth without external funding. Over months this limits strategic flexibility and raises funding risk if investment needs persist.

Rising leverage trend

An uptick in leverage, even if currently manageable, increases fixed financial obligations and sensitivity to interest-rate moves. If the trend continues, it could reduce financial resilience, raise financing costs and constrain capacity to pursue acquisitions or large-scale investments.

Zim Laboratories Ltd. Business Overview & Revenue Model

Company Description

ZIM Laboratories Limited develops, manufactures, and supplies pharmaceutical formulation and pre formulation ingredients in India and internationally. The company provides technology-based drug delivery solutions and non-infringing proprietary manufacturing processes for generic pharmaceutical products in semi-finished and finished categories/formulations, such as granules, pellets, taste masked powders, suspensions, tablets, capsules, and oral thin films. It serves therapeutic areas, such as urology, gastroenterology, cardiology, and anticoagulants, as well as antibiotics and anti-infectives, NSAIDs/pain analgesics, and vitamins and supplements. ZIM Laboratories Limited was incorporated in 1984 and is based in Nagpur, India.

How the Company Makes Money

Zim Laboratories generates revenue primarily by selling pharmaceutical formulation products. Key revenue streams include: (1) Domestic sales: revenue from marketing and distributing its branded or branded-generic formulations in India through its sales network and channel partners. (2) Export/international business: revenue from supplying finished dosage formulations to customers outside India, typically through distributor relationships and/or direct institutional and commercial sales, subject to regulatory approvals in the destination markets. (3) Contract development and manufacturing/third-party manufacturing: revenue earned by developing and/or manufacturing formulations for other pharmaceutical companies under contractual arrangements, where Zim is paid for development services and/or per-unit manufacturing supply. (4) Technology-/product-platform led opportunities: to the extent the company licenses or supplies products based on its drug-delivery platforms, it can earn income through product supply and, where applicable, milestone/royalty-like arrangements; specific, publicly confirmed licensing terms are null. Earnings are influenced by product mix, scale of manufacturing utilization, regulatory compliance and approvals for specific markets, pricing/competition in generics, and the ability to onboard and retain distribution/marketing partners; named significant partnerships are null.

Zim Laboratories Ltd. Financial Statement Overview

Summary

Zim Laboratories Ltd. shows strong revenue growth and operational efficiency with stable margins and improved operating cash flow. However, concerns include a decline in net profit margin and low free cash flow, alongside increased leverage.

Income Statement

Zim Laboratories Ltd. has demonstrated solid revenue growth over the years, with a notable increase from 2024 to 2025. Gross profit margins have improved, indicating efficient cost management. However, the net profit margin saw a decline in 2025 due to lower net income despite higher revenues. EBIT and EBITDA margins have been stable, showcasing operational efficiency, though the recent dip in EBIT margin is a concern.

Balance Sheet

The company maintains a strong equity position, with an improving equity ratio indicating a healthy balance between assets and liabilities. The debt-to-equity ratio is manageable, though it has increased slightly, hinting at rising leverage. ROE has fluctuated, reflecting changes in profitability but remains at a reasonable level.

Cash Flow

Operating cash flow has improved significantly, which is a positive sign for liquidity. However, free cash flow remains low, with capital expenditures consuming a large portion of operating cash flow. The free cash flow to net income ratio remains weak, indicating challenges in converting net income into cash.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	3.66B	3.74B	3.68B	3.99B	3.31B	3.07B
Gross Profit	1.85B	730.04M	1.86B	903.81M	1.67B	1.48B
EBITDA	431.55M	495.11M	454.76M	582.00M	452.62M	355.31M
Net Income	65.86M	121.65M	172.46M	244.34M	145.50M	73.17M
Balance Sheet
Total Assets	4.70B	4.72B	4.47B	3.42B	3.42B	3.25B
Cash, Cash Equivalents and Short-Term Investments	50.12M	20.37M	96.41M	64.66M	34.20M	13.93M
Total Debt	1.23B	1.18B	1.12B	620.00M	533.14M	823.20M
Total Liabilities	2.19B	2.20B	2.08B	1.41B	1.66B	1.64B
Stockholders Equity	2.51B	2.52B	2.39B	2.00B	1.76B	1.61B
Cash Flow
Free Cash Flow	40.45M	3.57M	-576.45M	15.00M	339.81M	253.74M
Operating Cash Flow	199.18M	411.55M	162.78M	381.68M	492.06M	318.51M
Investing Cash Flow	-155.70M	-399.27M	-730.13M	-362.04M	-145.71M	-58.81M
Financing Cash Flow	-34.19M	-91.05M	595.34M	5.46M	-329.70M	-259.74M

Zim Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 71.11
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZIMLAB, the sentiment is Negative. The current price of 71.11 is above the 20-day moving average (MA) of 68.64, below the 50-day MA of 71.21, and below the 200-day MA of 81.21, indicating a bearish trend. The MACD of -1.72 indicates Positive momentum. The RSI at 36.77 is Neutral, neither overbought nor oversold. The STOCH value of 19.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ZIMLAB.

Zim Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	79 Outperform	₹12.20B	10.01	―	―	13.32%	218.38%
ZIMLAB	63 Neutral	₹3.14B	19.99	―	―	-5.82%	-59.22%
MEDICAMEQ	55 Neutral	₹3.70B	56.53	―	0.26%	-9.16%	49.09%
LYKALABS	54 Neutral	₹1.90B	-338,564.26	―	―	4.04%	-35.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALBERTDAVD	51 Neutral	₹3.85B	6.87	―	0.66%	-13.51%	-122.00%
NECLIFE	46 Neutral	₹2.47B	7.63	―	―	-30.27%	-3470.06%

Zim Laboratories Ltd. Corporate Events

Zim Laboratories to Close Trading Window Ahead of December Quarter Results

Zim Laboratories Limited has announced the closure of its trading window for company securities starting 1 January 2026, in line with SEBI (Prohibition of Insider Trading) Regulations, 2015 and its internal code of conduct for regulating, monitoring and reporting trading by insiders. The restriction applies to designated persons, including promoters, directors, key managerial personnel, connected persons, specified employees and their immediate relatives, and will remain in force until 48 hours after the company discloses its financial results for the quarter and nine months ended 31 December 2025, underscoring ongoing adherence to regulatory norms and governance standards around unpublished price-sensitive information.